Announced
Completed
Financials
Tags
Venture Capital
Single Bidder
United States
Private
Completed
Private Equity
development of cures for infectious diseases
Cross Border
Minority
Acquisition
Friendly
Biotechnology
Synopsis
Arkin Bio Ventures, a healthcare investment company, led a $41m Series B round in Bluejay Therapeutics, a virology and liver disease-based company, with participation from other Synergenics, RiverVest Venture Partners, Yonjin Capital, Octagon Capital and InnoPinnacle International. “Bill and Alon’s extensive experience across therapeutic areas will be invaluable to Bluejay at this time of growth for our company. We are very excited to have them on the team," Dr. Keting Chu, Bluejay Therapeutics Founder, Chairman and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.